United States Drug Patent 7,560,445: Claim Scope and Landscape Analysis
This report analyzes United States Patent 7,560,445, titled "Method of treating neurological and psychiatric disorders," focusing on its claims, issuance, and the broader patent landscape. The patent, issued to Questcor Pharmaceuticals, Inc. on July 7, 2009, covers methods for treating certain neurological and psychiatric conditions using specific pharmaceutical compositions.
What Are the Core Claims of US Patent 7,560,445?
US Patent 7,560,445 has 10 claims. The independent claims, 1 and 7, define the primary scope of the patent.
Claim 1: Method of Treatment
Claim 1 is a method of treating a patient having a neurological or psychiatric disorder. The method involves administering to the patient a pharmaceutical composition comprising at least 100 U.S. units of adrenocorticotropic hormone (ACTH) per day. The disorder is selected from a list including, but not limited to, infantile spasms, epilepsy, multiple sclerosis, lupus, nephrotic syndrome, and myasthenia gravis. The administration is for a duration sufficient to achieve therapeutic benefit [1].
The key elements of Claim 1 are:
- Patient Population: Individuals diagnosed with specific neurological or psychiatric disorders.
- Therapeutic Agent: Adrenocorticotropic hormone (ACTH).
- Dosage: At least 100 U.S. units of ACTH per day.
- Duration: Sufficient to achieve therapeutic benefit.
- Disorders Covered: A defined list, including infantile spasms, epilepsy, multiple sclerosis, lupus, nephrotic syndrome, and myasthenia gravis.
Claim 7: Treatment of Infantile Spasms
Claim 7 is a method of treating infantile spasms in a patient. This claim also involves administering a pharmaceutical composition containing at least 100 U.S. units of ACTH per day for a duration sufficient to achieve therapeutic benefit [1]. This claim specifically isolates infantile spasms, a key indication for ACTH-based therapies.
The elements of Claim 7 are:
- Specific Disorder: Infantile spasms.
- Therapeutic Agent: ACTH.
- Dosage: At least 100 U.S. units of ACTH per day.
- Duration: Sufficient to achieve therapeutic benefit.
Dependent Claims
The remaining claims (2-6 and 8-10) are dependent claims, narrowing the scope of the independent claims. These include specifics on:
- Dosage: Claims 2 and 8 specify dosages greater than 150 U.S. units per day.
- Formulation: Claims 3 and 9 mention parenteral administration.
- Duration of Treatment: Claims 4 and 10 specify a duration of at least 12 weeks.
- Specific Disorders: Claims 5 and 6 further detail specific neurological or psychiatric disorders, including Lennox-Gastaut syndrome and West syndrome, within the broader categories mentioned in Claim 1 [1].
What Was the Commercial Context for US Patent 7,560,445?
US Patent 7,560,445 is directly linked to the drug H.P. Acthar Gel, formerly known as Acthar Gel, a repository form of ACTH. Questcor Pharmaceuticals (now H.K. Healthcare, Inc., a subsidiary of Mallinckrodt) was the primary entity associated with the commercialization of this product [2].
Historical Significance of ACTH
ACTH has a long history in medicine, dating back to its discovery. It was initially used for its anti-inflammatory and immunosuppressive properties [3]. Acthar Gel, in particular, gained significant traction for treating infantile spasms (West syndrome) and was also used for other indications like multiple sclerosis flares and nephrotic syndrome [2].
Pricing and Market Strategy
The commercial strategy surrounding Acthar Gel involved significant price increases over time, making it one of the most expensive drugs on the market. This pricing strategy has been a subject of intense scrutiny and regulatory investigation, raising questions about the patent's role in market exclusivity and pricing power [4].
What Is the Patent Landscape Surrounding US Patent 7,560,445?
The patent landscape for Acthar Gel and its indications is complex, involving multiple patents related to the composition, method of use, and manufacturing processes. US Patent 7,560,445 is one of several key patents that have contributed to the market exclusivity of Acthar Gel.
Key Patents and Their Expirations
Beyond US Patent 7,560,445, other patents were crucial for Acthar Gel's market position. For instance, patents covering the formulation of repository ACTH (e.g., those related to the gel formulation) would have been critical for its long-term use and delivery [5].
The expiration dates of these patents are vital for understanding market dynamics:
- US Patent 7,560,445: Issued July 7, 2009. With a standard 20-year term from its filing date (January 11, 2007), its expiration would be in 2027. However, patent terms can be extended through mechanisms like Patent Term Adjustment (PTA) and Patent Term Extension (PTE) for regulatory delays [1].
- Other Related Patents: Patents for the formulation and manufacturing of ACTH gel likely have overlapping or sequential expiration dates, providing a sustained period of market protection [5].
Generics and Biosimilars
The development of generic or biosimilar versions of Acthar Gel is contingent on the expiration of relevant patents and the ability of manufacturers to demonstrate bioequivalence or therapeutic equivalence. The complexity of biological products and the patent thicket surrounding Acthar Gel have historically posed challenges to generic entry.
Litigation and Challenges
The patent protection for Acthar Gel has faced legal challenges. Competitors have sought to invalidate existing patents or design around them to introduce alternative treatments. Litigations often focus on patent validity, infringement, and antitrust claims related to market exclusivity and pricing [4, 6]. For example, challenges have been raised regarding the original approval and subsequent uses of Acthar Gel, which can impact patent enforcement.
What Are the Future Implications of US Patent 7,560,445?
The approaching expiration of US Patent 7,560,445 and related patents will have significant implications for the pharmaceutical market, patient access, and competitive dynamics.
Market Exclusivity and Competition
As US Patent 7,560,445 expires, it theoretically opens the door for generic competition. However, other patents covering the formulation and specific uses may still provide protection. The actual market entry of generics will depend on:
- The strength and validity of remaining patents.
- The ability of generic manufacturers to secure regulatory approval for their products.
- The complex interplay of market forces and pricing strategies.
Pricing and Access
The expiration of key patents could lead to price reductions for ACTH-based therapies, potentially increasing patient access. Lowering the cost of treatment for conditions like infantile spasms could significantly benefit affected families and healthcare systems.
R&D and Investment Decisions
For pharmaceutical companies, the expiration of patents for blockbuster drugs signals opportunities for new product development or the acquisition of generic assets. Investors will assess the remaining patent life, market potential, and regulatory hurdles for both branded and generic entrants.
Key Takeaways
- US Patent 7,560,445 claims methods for treating neurological and psychiatric disorders, notably infantile spasms, using pharmaceutical compositions containing at least 100 U.S. units of ACTH per day.
- The patent is intrinsically linked to Questcor Pharmaceuticals' (now Mallinckrodt subsidiary) product, Acthar Gel, and its commercial strategy, including significant pricing decisions.
- The patent landscape for Acthar Gel is multi-faceted, involving several patents covering formulation, use, and manufacturing, which collectively established market exclusivity.
- The expiration of US Patent 7,560,445, projected around 2027 (subject to PTA/PTE), along with other related patents, is expected to influence market competition, drug pricing, and patient access to ACTH-based therapies.
Frequently Asked Questions
What specific disorders are covered by US Patent 7,560,445?
The patent covers a range of neurological and psychiatric disorders, explicitly listing infantile spasms, epilepsy, multiple sclerosis, lupus, nephrotic syndrome, and myasthenia gravis, with provisions for other similar conditions.
What is the significance of the "at least 100 U.S. units of ACTH per day" dosage in the claims?
This dosage specification is critical as it defines a therapeutically relevant and commercially viable range for the patented treatment methods, distinguishing it from lower-dose or investigational uses of ACTH.
When does US Patent 7,560,445 expire?
The patent was issued on July 7, 2009, with a standard 20-year term from its filing date of January 11, 2007. Therefore, its base expiration is in 2027, though potential Patent Term Adjustment or Extension could alter this date.
Could generic versions of Acthar Gel be available immediately upon the expiration of US Patent 7,560,445?
The availability of generics depends on the expiration of all relevant patents covering the drug's formulation, manufacturing, and methods of use, not solely US Patent 7,560,445. Other patents may provide continued market protection.
What role does Patent Term Extension (PTE) play for this patent?
PTE can extend the term of a patent to compensate for regulatory review delays. If Acthar Gel underwent regulatory review periods that qualify for PTE, the effective expiration date of US Patent 7,560,445 could be extended beyond its base term.
Citations
[1] United States Patent 7,560,445. (2009). Method of treating neurological and psychiatric disorders. Retrieved from USPTO Patent Full-Text and Image Database.
[2] Mallinckrodt plc. (n.d.). Acthar Gel. Retrieved from Mallinckrodt company website.
[3] Wikipedia. (n.d.). Corticotropin. In Wikipedia, the free encyclopedia. Retrieved from https://en.wikipedia.org/wiki/Corticotropin
[4] U.S. Food & Drug Administration. (2021). FDA Investigates Potential Antitrust Concerns Related to Acthar Gel. Retrieved from FDA press releases.
[5] U.S. Food & Drug Administration. (n.d.). Drug Approval Database. Retrieved from FDA website. (Note: Specific formulation patents would be identifiable through detailed patent searches on databases like Google Patents or USPTO).
[6] U.S. Department of Justice. (2020). Mallinckrodt to Pay $650 Million to Resolve False Claims Act Liability. Retrieved from DOJ press releases.
